Fig. 1.
Rev3 depletion sensitizes B-cell lymphomas to cisplatin in vitro and in vivo. (A) Quantitative RT-PCR (n ≥ 3) confirmation of target mRNA suppression using three distinct shRNAs targeting Rev3 in retrovirally transduced Eμ-myc; p19arf−/− lymphoma cells. Retroviral vectors coexpressed shRNAs and a GFP marker, and pure populations of infected cells were isolated by GFP sorting before RT-PCR. (B) Naïve lymphoma cell populations were transduced to an infection efficiency of 40–50% with Rev3 shRNAs, treated with cisplatin (0.5 and 1.0 μM), and monitored using GFP-based flow cytometry for changes in the relative percentage of shRNA-containing (GFP-positive) cells. n ≥ 3 for all samples. (C) Representative pseudocolored images showing the tumor burden in four individual mice (two control and two Rev3-knockdown mice) treated with cisplatin for 24 h. (D) Quantification of relative changes in tumor volume in control and Rev3-knockdown tumors before and 24 h after cisplatin treatment. n = 3 individual mice in each group. All quantified data shown represent the mean ± SD. P values were determined using Student's t tests.